Navigation Links
Par Pharmaceutical Receives Final Approval To Market Tretinoin Capsules
Date:10/25/2012

WOODCLIFF LAKE, N.J., Oct. 25, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its operating subsidiary, Anchen Pharmaceuticals, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for tretinoin capsules, 10 mg.  Tretinoin capsules is the generic version of Vesanoid® capsules and is used in the treatment of acute promyelocytic leukemia.  Par expects to begin shipping the product before the end of the month. 

According to IMS Health data, annual U.S. sales of tretinoin are approximately $29 million. 

Important Information about Tretinoin Capsules

Tretinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARalpha gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated.  Tretinoin is for the induction of remission only.  The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with tretinoin. 

Tretinoin is contraindicated in patients with a known hypersensitivity to tretinoin, any of its components, or other retinoids.  

Patients with acute promyelocytic leukemia (APL) are at high risk in general and can have severe adverse reactions to tretinoin.   About 25% of patients with APL treated with tretinoin have experienced a syndrome called the retinoic-acid-APL (RA-APL) syndrome characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural a
'/>"/>

SOURCE Par Pharmaceutical Companies
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015   Today: A ... teens nationwide has prompted The Addiction Advisor to ... usage in just 5 minutes. The drug screening ... tools to drug test for thirteen (13) of ... in confidential packaging with instructions and recommendations, parents ...
(Date:6/3/2015)... -- PARI Respiratory Equipment has won a 2015 American Package Design ... the FDA on December 2, is the first co-packaging of ... Nebulizer for patients with cystic fibrosis. ... this unique product offering of nebulized drug and device.  In ... we also wanted to convey that the components suit each ...
(Date:6/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ) ... Future of Pharmaceutical Outsourcing" report to their ... desperate need to develop better drugs with high ... been increasingly utilizing external resources to increase their ... their internal operation. Their outsourcing demands and proportions ...
Breaking Medicine Technology:The Drug Detective Is A Simple Test That Could Save Your Child's Life 2Kitabis Pak Wins American Package Design Award 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... MedShape Solutions, Inc., the industry leader in ... has developed new, larger sizes of its ExoShape ... that simplifies and improves soft tissue graft fixation ... announcement comes after MedShape received the U.S. Food ...
... ActiveCare, Inc. (ACAR.OB) a leader in senior care technology, ... up the rollout of ActiveCare,s ActiveHome products and services ... its, comprehensive ActiveHome Monitoring System.  To guide this market ... his team has extensive experience increasing sales and marketing ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing 2With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing 3
(Date:6/3/2015)... 2015 Johnson & Johnson and its ... to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) filed ... allegedly used to market the antipsychotic drug. Court ... the Arkansas Attorney General moved to dismiss the case ... Risperdal settlement amounts to just a fraction of the ...
(Date:6/3/2015)... 03, 2015 “ Harmony ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... wants to improve some aspect of their life. , A ... for people with difficulties in their life. However, hypnotherapy is ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... 03, 2015 On the heels of a ... industry by 2020 ( click here to review news ... believe Baltimore has the talent to become a ... genetic code and other biological data are collected and analyzed ... “Baltimore contains all the elements of a perfect storm for ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Dr. Steven ... York Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, ... on weekdays to his practice. In most cases, depending on ... of the day they call, they will be seen by ... first priority as a cardiologist is to ensure that people ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2
... ... Institute to identify regions of the dengue virus and Mycobacterium tuberculosis that can be targeted ... Melbourne, ... (NASDAQ Capital Market: CBTE), is pleased to announce that it has been awarded a major ...
... , NASDAQ: CRME ... Pharma Corp. (NASDAQ: CRME / TSX: COM) today ... its directors, officers and employees (each a "restricted person") to ... pursuant to applicable Canadian and U.S. securities laws, including the ...
... Researchers from Boston University School of Medicine (BUSM) have ... of emphysema. The study, which appears on-line in the ... therapeutic genes in lung tissue for a lifetime after only ... most common inherited form of emphysema seen in young people ...
... less clogged in those who nurse infants, study finds, , ... to breast-feed because of the numerous health benefits it offers ... the health of the mothers, hearts later in life. ... that those who had not breast-fed were much more likely ...
... ... rid of their worst menopause and perimenopause symptoms. Don’t Pause contains other natural supplements ... women experience as they age. , ... (PRWEB) December 21, 2009 -- When a woman starts going through ...
... , NEW YORK, Dec. 21 The Center to Advance ... Diane E. Meier, MD , a pioneer in palliative care, has ... of four 2009-2010 Health and Aging Policy Fellows , Dr. ... process at the Federal level. The HELP committee has jurisdiction over ...
Cached Medicine News:Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 2Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 3Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 2Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 3Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 5Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 6Health News:Researchers discover gene therapy to prevent progression of emphysema 2Health News:Breast-Feeding May Protect a Woman's Heart 2Health News:Breast-Feeding May Protect a Woman's Heart 3Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 2Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 3Health News:Center to Advance Palliative Care Director and MacArthur Recipient, Diane E. Meier, MD, Accepts Fellowship Post With Senate HELP Committee 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: